Red Light Holland Corp.

corporate_fare Company Profile

Red Light Holland Corp.

FLHLF·OTC·Life Sciences·CIK 0001836747

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's primary drug candidates include PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. Additionally, it is developing AEX010 ayahuasca, which is in the preclinical stage, and AEX020 monoamine oxidase inhibitor, also in the preclinical stage. The company conducts in-house human clinical trials and licenses its technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.

Red Light Holland Corp. (OTC:FLHLF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for FLHLF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-04-27, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above.

Recent high-impact activity:

Filament Health Shareholders Approve Acquisition by Red Light Holland, Paving Way for Close (2026-04-27)
Red Light Holland to Acquire Filament Health, Gaining 76 Patents and Key Regulatory Licenses for Psychedelic Drug Development (2026-03-10)

show_chartPrice Chart

Loading chart...

feed FLHLF - Latest Insights

Filing Type

Date Range

FLHLF

Apr 27, 2026, 7:30 AM EDT

Source: TMX Newsfile

Importance Score:

Filament Health Shareholders Approve Acquisition by Red Light Holland, Paving Way for Close

Price at Filing: $0.0001

Real-time Price: $0.0001

Change: $0 (0%)

Market Cap: N/A

Sentiment: Neutral

View Wiseek Article

FLHLF

Mar 10, 2026, 4:40 PM EDT